Tags : Head and Neck Cancer

Biotech

AstraZeneca and Innate Pharma to Advance Monalizumab in a P-III

Shots: AstraZeneca will evaluate the combination of Monalizumab with Cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with the anticipated onset of the study in 2020 In Apr’2015, AstraZeneca and Innate collaborated to co-develop & co-commercialize Monalizumab for $1.275B out of which Innate has received $350M and […]Read More